Christian Angermayer
Christian Angermayer is the Founder and CEO of Apeiron Investment Group, his private investment firm and family office focused on life sciences, biotechnology, fintech, AI, hospitality, and cryptocurrencies. He also founded Presight Capital, Apeiron’s flagship venture fund. A prominent serial entrepreneur and investor, Angermayer has founded three unicorns and been the lead investor in four unicorns and two decacorns. He is a leading advocate for human enhancement, supporting scientific innovations that expand physical and mental potential. Angermayer is also one of Europe’s most active investors in fintech, with a strong emphasis on crypto and blockchain-based business models.
CURRENT AFFILIATIONS
Founder, Rejuveron Life Sciences
Founder, Cambrian Biopharma
Board of Directors, Atai Life Sciences
Board Member, Hayek Institute
Sponsor, XPRIZE Healthspan
Young Global Leader, World Economic Forum
Member, Milken Institute Young Leaders' Circle
Partner, Munich Security Conference
Advisory Council Member, Academy for Health and Lifespan Research
CAREER
Angermayer is an active thought leader who has created, co-founded and invested in numerous successful companies.
He has raised over $2bn for his portfolio companies and has been involved in more than 50 successful IPO- and M&A-transactions either as an entrepreneur, investor or advisor.
The Angermayer Policy and Innovation Forum convenes international heads of states, politicians, investors, and scientists coming together to discuss and address global priorities.
He is also a driving force behind the world’s leading BCI developer, Blackrock Neurotech.
ART & MEDIA
Angermayer is passionate about the arts and film and has been the executive producer of 26 feature films and numerous theatre productions.
He owns an extensive art collection that includes ancient artifacts highlighting the role that psychedelics have played in human history.
He has been featured in numerous financial media outlets and publications, including Forbes, Bloomberg, Fortune, The Wall Street Journal, Business Insider, and Real Vision.